The 'skinny pen' semaglutide question: what the decision actually involves

Semaglutide (Wegovy) is a GLP-1 receptor agonist: it mimics a gut hormone to reduce appetite and slow gastric emptying, helping you eat less without relying on willpower alone.
The injection schedule starts at 0.25 mg weekly and is titrated by a prescriber through several dose steps up to a maximum of 2.4 mg (or 7.2 mg under the MHRA's 2026 approval for the higher-dose pen).
In the STEP 1 clinical trial, participants using semaglutide 2.4 mg lost an average of around 15% of body weight over 68 weeks, alongside reduced-calorie diet and increased activity.
Wegovy carries a Black Triangle (▼) designation, meaning it is subject to additional monitoring by the MHRA; suspected side effects should be reported via the Yellow Card scheme.

Semaglutide is the active ingredient in Wegovy, a once-weekly injection pen licensed in the UK for weight management. The term 'skinny pen' is a colloquial shorthand — worth correcting once and moving on. As a prescription-only medicine, it can only be supplied following a clinical assessment by a registered prescriber who decides whether it is suitable for you specifically. That decision rests on several factors, and understanding them is the most useful thing this page can give you.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

Making sense of the semaglutide pen: the four decisions most people face

Is semaglutide the right medicine for your situation, or would tirzepatide suit you better?

This is the first fork. Semaglutide (Wegovy) activates a single gut-hormone receptor (the GLP-1 pathway) which reduces appetite and slows how quickly food leaves your stomach. Tirzepatide (Mounjaro) activates two receptors, GLP-1 and GIP. In the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks. That said, head-to-head data is one input, not a verdict. Individual response varies, contraindications differ, and some people find one medicine's side-effect profile suits their daily life better than the other's.

Your medical history shapes this choice more than a trial average does. A prescriber will look at your weight-related conditions, any medicines you already take, and whether there are reasons to prefer one agent over another. You can read more about how the two compare on the Wegovy treatment overview page, or explore the broader picture on the weight-loss treatment options page. The NHS medicines page for semaglutide is also a clear, reliable starting point for the clinical basics.

What does actually using the semaglutide pen look like week to week?

Practical reality matters here, because a medicine you can sustain is worth more than one you abandon after two months. If you want to understand exactly how the device works before you begin, the semaglutide pen guide covers everything from loading to disposal in plain language. You inject once a week into the abdomen, thigh, or upper arm, rotating the site each time. Injection depth, needle length, and exact technique are worth getting right from the start; the guide to injecting semaglutide walks through the process step by step.

Storage is straightforward but non-negotiable: the pen lives in the fridge, ideally in the door compartment where temperature stays stable. Room-temperature tolerance exists but the exact window is set out in the Patient Information Leaflet, always follow that, not a summary elsewhere. Used needles go into a sharps container and are disposed of through your local pharmacy or household clinical waste scheme. Many people find a short weekly routine (same day, same time, stored item checked the night before) makes the habit stick. If you are comparing devices or moving between dose stages, the overview of semaglutide pens explains the differences between the pens used at each stage of treatment. None of this is complicated, but it does need to be done correctly and consistently.

What should you realistically expect in the first weeks, and when is a side effect a reason to act?

The most common side effects are gastrointestinal: nausea, loose stools, constipation, reflux and fatigue. They tend to be most noticeable after a new dose begins and often ease within a week or two as your body adjusts. Eating smaller portions, avoiding very fatty meals, and staying well hydrated all help. The semaglutide injection information page covers the practical side-effect management points in more detail.

Some symptoms warrant same-day medical attention rather than a wait-and-see approach. Severe, persistent stomach pain that spreads to your back (with or without vomiting) can indicate acute pancreatitis, a known but infrequent side effect that the MHRA highlighted specifically in a Drug Safety Update issued in January 2026. Signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing, rapid heartbeat) also require emergency care. Suspected side effects from any medicine in this class can be reported through the MHRA's Yellow Card scheme, which helps regulators track safety signals in real time.

How does private access work, and what does the cost picture actually include?

Wegovy is available on the NHS through specialist weight management services under NICE guidance, but waiting lists are long and eligibility criteria are specific. Private access through a regulated pharmacy removes the wait. The question then becomes what a private prescription actually covers, and this varies considerably between providers. Some advertise a headline figure that excludes the consultation fee, delivery, or aftercare support. For a broader sense of what private semaglutide treatment typically costs in the UK and what those figures do and don't include, the Wegovy cost and access guide sets out the context honestly.

At nume, one price covers the free consultation, clinical review by a GPhC-registered Independent Prescriber, prescription, and free next-working-day tracked delivery. There are no subscriptions and no automatic renewals; every repeat order goes through a fresh clinical check. That is the right frame for evaluating any online pharmacy offering a prescription medicine: not price in isolation, but what the price actually buys you in terms of clinical oversight. If you are ready to take the next step, our prescribers are available to review your details today, speak to our prescribers through a free consultation and get a same-day clinical decision.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions